Ruiz-Argüelles Guillermo J, Díaz-Hernández Angeles, Manzano Carlos, Ruiz-Delgado Guillermo J
Centro de Hematología y Medicina Interna de Puebla, Puebla, PUE, Mexico.
Hematology. 2007 Jun;12(3):255-6. doi: 10.1080/10245330701214160.
Two hundred and forty one patients with iron deficiency anemia (IDA) were identified in a single institution over a 24-year period; of these, 75 individuals were studied as the result of persistent IDA despite the administration of oral iron hydroxide polymatose (IP). The levels of hemoglobin when the patients were referred for study after being given oral IP had a median of 10.3 g/dl; after administration of oral iron fumarate during periods ranging from 1 to 14 months, the levels of hemoglobin rose to a median of 12.5 g/dl (p>0.01). Our data support previous observations made in other countries about the ineffectiveness of oral IP in the treatment of individuals with IDA and should alert the clinician to avoid unnecessary consultations and misdiagnosis.
在24年期间，一家机构共确诊了241例缺铁性贫血（IDA）患者；其中，75例患者尽管服用了口服聚麦芽糖铁（IP），但仍患有持续性IDA，因此接受了研究。这些患者在服用口服IP后被转诊进行研究时，血红蛋白水平中位数为10.3 g/dl；在服用口服富马酸铁1至14个月后，血红蛋白水平升至中位数12.5 g/dl（p>0.01）。我们的数据支持了其他国家先前关于口服IP治疗IDA患者无效的观察结果，并应提醒临床医生避免不必要的会诊和误诊。
